The estimated Net Worth of Partners Lpjohnson David Ed... is at least $71 Миллион dollars as of 30 August 2024. Partners Ed owns over 150,000 units of Liquidia Corp stock worth over $70,999,220 and over the last 3 years Partners sold LQDA stock worth over $0.
Partners has made over 7 trades of the Liquidia Corp stock since 2022, according to the Form 4 filled with the SEC. Most recently Partners bought 150,000 units of LQDA stock worth $1,426,500 on 30 August 2024.
The largest trade Partners's ever made was buying 1,764,705 units of Liquidia Corp stock on 18 April 2022 worth over $8,999,996. On average, Partners trades about 520,191 units every 108 days since 2022. As of 30 August 2024 Partners still owns at least 6,994,997 units of Liquidia Corp stock.
You can see the complete history of Partners Ed stock trades at the bottom of the page.
Partners's mailing address filed with the SEC is 780 THIRD AVENUE780 THIRD AVENUE, 30TH FLOOR30TH FLOOR, NEW YORKNEW YORK, NYNY, 1001710017.
Over the last 6 years, insiders at Liquidia Corp have traded over $16,750,945 worth of Liquidia Corp stock and bought 12,456,625 units worth $100,694,400 . The most active insiders traders include Forest Baskett, Scott D Sandell и Peter J Barris. On average, Liquidia Corp executives and independent directors trade stock every 18 days with the average trade being worth of $1,467,274. The most recent stock trade was executed by Russell Schundler on 30 August 2024, trading 2,344 units of LQDA stock currently worth $23,792.
liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.
Liquidia Corp executives and other stock owners filed with the SEC include: